Variable |
ABO-matched |
Major MM |
Minor MM |
Bi-Dir MM |
P |
Patients, n |
38 (44.7%) |
17 (20.0%) |
21 (24.7%) |
9
(10.6%) |
|
Age, years
(median ± SD)
|
6.73 ± 3.3
|
7.58 ± 3.75
|
5.8 ± 3.82
|
6.77 ± 4.41
|
0.521
|
Sex |
|
|
|
|
0.674 |
Male/female |
22/16 |
8/9 |
9/12 |
4/5 |
|
Disease classification |
|
|
|
|
0.132 |
SAA |
25 (65.8%) |
10 (58.8%) |
16 (76.2%) |
9 (100.0%) |
|
VSAA |
13 (34.2%) |
7 (41.2%) |
5 (23.8%) |
0 (0.0%) |
|
Donor type |
|
|
|
|
0.690 |
HID |
16 (42.1%) |
10 (58.8%) |
11 (52.4%) |
4 (44.4%) |
|
MSD |
6 (15.8%) |
1 (5.9%) |
3 (14.3%) |
0 (0.0%) |
|
UD |
16 (42.1%) |
6 (35.3%) |
7 (33.3%) |
5 (55.6%) |
|
Ferr (range) |
849.4 (627.1–1071.7) |
2195.0 (-1085.8 to
5475.8) |
1377.9 (494.2–2261.6) |
741.1 (394.9–1087.2) |
0.701 |
MNC, ×108/L (median ± SD) |
8.2 ± 1.2 |
8.5 ±
3.5 |
8.7 ± 1.5 |
8.3 ± 1.3 |
0.844 |
CD34, ×106/L (median ± SD) |
6.0 ± 2.6 |
5.7
± 2.5 |
5.3 ± 2.2 |
4.3 ± 1.0 |
0.281 |
Neutrophil engraftment |
13.0 (12.9–14.7) |
12.0 (12.4–15.0) |
13.0 (12.3–15.6) |
13.0 (11.8–14.0) |
0.896 |
Platelet
engraftment
|
16.2 ± 5.7
|
16.2 ± 6.0
|
16.6 ± 5.6
|
14.3 ± 3.2
|
0.785
|
aGVHD classification |
15 (39.5%) |
3 (17.7%) |
5 (23.8%) |
1 (11.1%) |
0.186 |
cGVHD classification |
5 (13.2%) |
2 (11.76%) |
5 (23.81%) |
1 (11.1%) |
0.740 |
Follow-up period, months |
30.2 ± 23.4 |
30.9 ± 22.2 |
32.6 ±
14.0 |
38.7 ± 19.5 |
0.529 |